Literature DB >> 23706308

HPV 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition.

Nicholas A Wallace1, Stephen L Gasior, Zachary J Faber, Heather L Howie, Prescott L Deininger, Denise A Galloway.   

Abstract

The expression of the E6 protein from certain members of the HPV genus β (β HPV 5 and 8 E6) can disrupt p53 signaling by diminishing the steady state levels of two p53 modifying enzymes, ATR and p300. Here, we show that β-HPV 5 and 8 E6 are also capable of reducing the steady state levels of another p53 modifying enzyme, ATM, and as a result restrict LINE-1 retrotransposition. Furthermore, we show that the reduction of both ATM and LINE-1 retrotransposition is dependent upon the ability of β-HPV 8 E6 to bind and degrade p300. We use inhibitors and dominant negative mutants to confirm that ATM is needed for efficient LINE-1 retrotransposition. Furthermore, neither sensitivity to LINE-1 expression nor LINE-1 induced DSB formation is altered in an ATM deficient background. Together, these data illustrate the broad impact some β-HPVs have on DNA damage signaling by promoting p300 degradation.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23706308      PMCID: PMC3873879          DOI: 10.1016/j.virol.2013.04.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  80 in total

Review 1.  The many substrates and functions of ATM.

Authors:  M B Kastan; D S Lim
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

2.  DNA repair mediated by endonuclease-independent LINE-1 retrotransposition.

Authors:  Tammy A Morrish; Nicolas Gilbert; Jeremy S Myers; Bethaney J Vincent; Thomas D Stamato; Guillermo E Taccioli; Mark A Batzer; John V Moran
Journal:  Nat Genet       Date:  2002-05-13       Impact factor: 38.330

3.  Carcinogenicity of human papillomaviruses.

Authors:  Vincent Cogliano; Robert Baan; Kurt Straif; Yann Grosse; Béatrice Secretan; Fatiha El Ghissassi
Journal:  Lancet Oncol       Date:  2005-04       Impact factor: 41.316

4.  Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition.

Authors:  Q Feng; J V Moran; H H Kazazian; J D Boeke
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

5.  Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

Authors:  D Cortez; Y Wang; J Qin; S J Elledge
Journal:  Science       Date:  1999-11-05       Impact factor: 47.728

6.  Enhanced phosphorylation of p53 by ATM in response to DNA damage.

Authors:  S Banin; L Moyal; S Shieh; Y Taya; C W Anderson; L Chessa; N I Smorodinsky; C Prives; Y Reiss; Y Shiloh; Y Ziv
Journal:  Science       Date:  1998-09-11       Impact factor: 47.728

7.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.

Authors:  S Matsuoka; G Rotman; A Ogawa; Y Shiloh; K Tamai; S J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

8.  Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types.

Authors:  M Thomas; L Banks
Journal:  J Gen Virol       Date:  1999-06       Impact factor: 3.891

9.  Vanillins--a novel family of DNA-PK inhibitors.

Authors:  Stephen Durant; Peter Karran
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

10.  Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association.

Authors:  Heather L Howie; Jennifer I Koop; Joleen Weese; Kristin Robinson; Greg Wipf; Leslie Kim; Denise A Galloway
Journal:  PLoS Pathog       Date:  2011-08-25       Impact factor: 6.823

View more
  23 in total

Review 1.  Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses.

Authors:  Nicholas A Wallace; Denise A Galloway
Journal:  Semin Cancer Biol       Date:  2014-01-08       Impact factor: 15.707

Review 2.  DNA damage response is hijacked by human papillomaviruses to complete their life cycle.

Authors:  Shi-Yuan Hong
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

3.  Human papillomaviruses: research priorities for the next decade.

Authors:  Erika Langsfeld; Laimonis A Laimins
Journal:  Trends Cancer       Date:  2016-05

4.  High-Risk Alphapapillomavirus Oncogenes Impair the Homologous Recombination Pathway.

Authors:  Nicholas A Wallace; Sujita Khanal; Kristin L Robinson; Sebastian O Wendel; Joshua J Messer; Denise A Galloway
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

5.  Beta Human Papillomavirus 8E6 Attenuates LATS Phosphorylation after Failed Cytokinesis.

Authors:  Dalton Dacus; Celeste Cotton; Tristan X McCallister; Nicholas A Wallace
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

6.  Beta human papillomavirus E6 expression inhibits stabilization of p53 and increases tolerance of genomic instability.

Authors:  Nicholas A Wallace; Kristin Robinson; Denise A Galloway
Journal:  J Virol       Date:  2014-03-19       Impact factor: 5.103

7.  β-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation.

Authors:  Nicholas A Wallace; Kristin Robinson; Heather L Howie; Denise A Galloway
Journal:  PLoS Pathog       Date:  2015-03-24       Impact factor: 6.823

8.  The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma.

Authors:  Jaime S Horton; Alexander J Stokes
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

Review 9.  Guardian of the Human Genome: Host Defense Mechanisms against LINE-1 Retrotransposition.

Authors:  Yasuo Ariumi
Journal:  Front Chem       Date:  2016-06-28       Impact factor: 5.221

Review 10.  Post-Transcriptional Control of LINE-1 Retrotransposition by Cellular Host Factors in Somatic Cells.

Authors:  Javier G Pizarro; Gaël Cristofari
Journal:  Front Cell Dev Biol       Date:  2016-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.